VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.

VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.